East China University of Technology intends to grant 150 million yuan of DHODH inhibitor-related patents to Hainan Hai medicine

On January 6, Hainan Hai Pharmaceuticals announced that it had recently signed a Patent Transfer Contract with East China University of Technology for DHODH inhibitor S-416-related patents, and that East China University of Technology had patents related to DHODH inhibitor S-416, and Hainan Hai Pharmaceutical was granted a patent for DHODH inhibitors for RMB150 million, with a landmark installment of the patent transfer fee.
DHODH inhibitors target is hydrochloric acid dehydrogenase (DHODH), currently clinically DHODH inhibitors are mainly used for rheumatoid arthritis, lupus nephritis, multiple sclerosis and other autoimmune diseases, a number of in-body and clinical studies show that drugs to suppress the target have anti-inflammatory, anti-tumor, antimalarial, anti-viral and other effects.
, the basic situation name of the partners: East China University of Technology Unified Social Credit Code: 12100000425010757A Legal Representative: Qu Jingping Address: 130 Meilu Road, Xuhui District, Shanghai Second, DHODH inhibitor S-416 the main content of the patent transfer contract transfer party (Party A): Hainan Hai Pharmaceutical Co., Ltd. and Party (Party B): East China University of Technology III, the scope of the transfer target: DHODH inhibition for Party B application The global interests of Chinese patents related to agent S-416, patents entering country-specific stages through PCT applications, and corresponding division patents, including patent rights covering authorized patents for DHODH inhibitor S-416, and patent applications, including the following patents: 4. The transfer payment, the milestone payment and the sales commission Party A shall, in accordance with the contract, pay the patent transfer fee to Party B in milestone installments, including the total amount of RMB 150 million paid between the signing of this contract and the period during which the DHODH inhibitors obtain the drug approval number, After the DHODH inhibitor is listed, the sales credit is paid as agreed in Clause 3.4.
15 working days after the entry into force of this contract, Party A shall pay 5% of the first transfer fee, i.e. RMB7.5 million.
Subsequent Party A will, in accordance with the progress of DHODH inhibitor research, receive clinical trial notifications, complete Phase I clinical studies, complete Phase II clinical studies, submit new drug declarations for production and obtain acceptance numbers, obtain drug approval numbers and other node completion, and adopt a landmark installment payment method to pay transfer fees.
DHODH inhibitors after the market sales of a discount: (A) DHODH inhibitors corresponding to the preparation and other products on the market, Party A shall be in accordance with the above-mentioned products in each financial year of sales revenue (excluding marketing expenses and taxes spent by Party A customers) in accordance with the agreed proportion, to Party B to pay a rate.
(B) payment of commission fees shall be from the date of listing of DHODH inhibitors to the expiration of the protection period of this technical compound patent (patent application number CN201510961003.6).
(C) Party A provides Party B with actual sales for the previous year at the end of the fifth month of each financial year and pays a one-time sales credit for the previous year.
3 years from the date of the contract, Party A must apply for a clinical trial of antiviral adaptation and obtain a clinical trial notice.
Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mace Medical and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here